Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

The study aims to evaluate the efficacy of the regimen CLAM in relapsed or refractory AML when used as first salvage for patients to relapse or fail after standard treatment with daunorubicin/cytarabine induction.

Sex

All

Minimum age

18 Years

Maximum age

65 Years

Inclusion Criteria:

1. Relapsed or refractory acute myeloid leukemia (AML) after one first-line chemotherapy regimen
2. Patients aged 18 - 65 inclusively
3. European Cooperative Oncology Group (ECOG) performance status of less than 2

Exclusion Criteria:

1. Patients aged less than 18 or above 65
2. ECOG performance status of 2 or more
3. Acute promyelocytic leukaemia
4. Uncontrolled active infection
5. Uncontrolled arrhythmia
6. Altered renal dysfunction with serum creatinine \> 1.5 x ULN and/or creatinine clearance \< 50 mL/min
7. Significant neurologic (grade \> 2) or psychiatric disorder, dementia or seizures
8. Clinical symptoms suggesting active central nervous system leukemia
9. Severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock or disseminated intravascular coagulation
10. Patients with known HIV, Hepatitis B or C infection or history of cirrhosis
11. Patients Significant hepatic dysfunction: Direct bilirubin \> 1.5 x upper limit of normal (ULN) for age; ALT or AST \> 3 x upper limit of normal (ULN) for age; Lipase \> 2.0 x upper limit of normal (ULN) for age
12. Females of childbearing potential must have a negative pregnancy test

• BACKGROUNDFaderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol. 2008 Mar;15(2):101-7. doi: 10.1097/MOH.0b013e3282f46e94. PMID 18300755
• BACKGROUNDFaderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15;113(8):2090-6. doi: 10.1002/cncr.23816. PMID 18756533
• BACKGROUNDSampat K, Kantarjian H, Borthakur G. Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222. PMID 19715446
• BACKGROUNDBecker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011 Oct;155(2):182-9. doi: 10.1111/j.1365-2141.2011.08831.x. Epub 2011 Aug 18. PMID 21848522
• BACKGROUNDTse E, Leung AY, Sim J, Lee HK, Liu HS, Yip SF, Kwong YL. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol. 2011 Nov;90(11):1277-81. doi: 10.1007/s00277-011-1223-2. Epub 2011 Apr 1. PMID 21455604
• BACKGROUNDLeung AY, Tse E, Hwang YY, Chan TS, Gill H, Chim CS, Lie AK, Kwong YL. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. Am J Hematol. 2013 Jun;88(6):485-91. doi: 10.1002/ajh.23439. Epub 2013 May 2. PMID 23512868
• BACKGROUNDNazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients </=60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9.